VJOncology is committed to improving our service to you

ASCO 2020 | BRCA and RAB: prognostic biomarkers in recurrent ovarian cancer

VJOncology is committed to improving our service to you

Elizabeth Swisher

Elizabeth Swisher, MD, Seattle Cancer Care Alliance, University of Washington Medical Center, Seattle, WA, discusses the mutational status of BRCA and RAB proteins and how this can be used prognostically as a biomarker for long-term durable responses to rucaparib treatment in recurrent ovarian cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter